Optimizing the sequence of anti-EGFR targeted therapy in EGFR-mutant lung cancer

Metastatic EGFR-mutant lung cancers are sensitive to the first- and second- generation EGFR tyrosine kinase inhibitors (TKIs), gefitinib, erlotinib, and afatinib, but resistance develops. Acquired resistance (AR) to gefitinib or erlotinib occurs most commonly (>50%) via the emergence of a second-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Meador, Catherine B., Jin, Hailing, de Stanchina, Elisa, Nebhan, Caroline A., Pirazzoli, Valentina, Wang, Lu, Lu, Pengcheng, Vuong, Huy, Hutchinson, Katherine E., Jia, Peilin, Chen, Xi, Eisenberg, Rosana, Ladanyi, Marc, Politi, Katerina, Zhao, Zhongming, Lovly, Christine M., Cross, Darren A. E., Pao, William
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4338015/
https://ncbi.nlm.nih.gov/pubmed/25477325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0723
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados